Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies.

ABSTRACT:

Background

Brain radiotherapy is used in the management of melanoma brain metastases (MBM) and can result in radionecrosis. Anti-PD-1 is active in the brain and may increase the risk of radionecrosis when combined with radiotherapy. We studied the incidence, associated factors and management of radionecrosis in longer-term survivors with MBM treated with this combination.

Methods

Patients with MBM treated with radiotherapy and anti-PD-1 who survived >1 year were identified to determine radionecrosis incidence (Cohort A, n = 135). Cohort A plus additional radionecrosis cases were examined for factors associated with radionecrosis and management (Cohort B, n = 148).

Results

From Cohort A, 17% developed radionecrosis, with a cumulative incidence at 2 years of 18%. Using

SUBMITTER: Pires da Silva I 

PROVIDER: S-EPMC8258671 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature